Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit?
File version
Author(s)
Halliday, Catriona L
Rai, Neela J
Jayawardena, Menuk
Hasan, Tasnim
Kok, Jen
Nayyar, Vineet
Gottlieb, David J
Gilroy, Nicole M
Chen, Sharon CA
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Background: Early, accurate diagnosis of invasive fungal disease (IFD) improves clinical outcomes. 1,3-beta-d-glucan (BDG) (Fungitell, Associates of Cape Cod, Inc., Falmouth, MA, USA) detection can improve IFD diagnosis but has been unavailable in Australia. Aims: To assess performance of serum BDG for IFD diagnosis in a high-risk Australian haematology population. Methods: We compared the diagnostic value of weekly screening of serum BDG with screening by Aspergillus polymerase chain reaction and Aspergillus galactomannan in 57 at-risk episodes for the diagnosis of IFD (proven, probable, possible IFD). Results: IFD episodes were: proven (n = 4); probable (n = 4); possible (n = 18); and no IFD (n = 31). Using two consecutive BDG results of ≥80 pg/mL to call a result ‘positive’, the sensitivity, specificity, positive predictive value and negative predictive value was 37.5%, 64.5%, 23.1% and 80.7% respectively. For invasive aspergillosis, test performance increased to 50%, 90.3%, 57.1% and 87.5% respectively if any two of serum BDG/Aspergillus polymerase chain reaction/galactomannan yielded a ‘positive’ result. In proven/probable IFD, five of eight episodes returned a positive BDG result earlier (mean 6.6 days) than other diagnostic tests. False-negative BDG results occurred in three of eight episodes of proven/probable IFD, and false positive in 10 of 31 patients with no IFD. Erratic patterns of BDG values predicted false positive results (P = 0.03). Using serum BDG results, possible IFD were reassigned to either ‘no’ or ‘probable’ IFD in 44% cases. Empiric anti-fungal therapy use may have been optimised by BDG monitoring in 38.5% of courses. Conclusions: The BDG assay can add diagnostic speed and value but was hampered by low sensitivity and positive predictive value in Australian haematology patients.
Journal Title
Internal Medicine Journal
Conference Title
Book Title
Edition
Volume
52
Issue
3
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Haematology
Clinical sciences
Public health
Health services and systems
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
beta-d-glucan
Persistent link to this record
Citation
Garnham, K; Halliday, CL; Rai, NJ; Jayawardena, M; Hasan, T; Kok, J; Nayyar, V; Gottlieb, DJ; Gilroy, NM; Chen, SCA, Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit?, Internal Medicine Journal, 2022, 52 (3), pp. 426-435